STAG Industrial

EastGroup Properties

Equinix

One Liberty Properties

EPR Properties

American Tower

Healthcare Realty Trust Inc

Gaming and Leisure Properties

Apartment Income REIT Corp

CTO Realty Growth

GRI Bio Inc

RDOG tracks an equal-weighted index that selects the five highest yielding US REITs within nine REIT segments.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU

GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR

GRI Bio kicks-off the series by explaining what recently published preclinical data on its GRI-0803 Lupus development program means for its overall advancement FRENCHTOWN, NJ / ACCESSWIRE / August 16, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the launch of its Virtual Investor "What This Means" Series. The series is designed to provide investors with context to press releases directly from company management teams.

JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series

Rapidly advancing c linical pipeline across multiple high-value i nflammatory, f ibrotic and a utoimmune d iseases

GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Data p resented at The Autoimmunity Conference h osted by the Federation of American Societies for Experimental Biology (FASEB)

GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

American Resources Corp

Live video webcasts with moderated interactive discussion with American Resources Corporation (NASDAQ:AREC) and GRI Bio (NASDAQ:GRI), respectively FRENCHTOWN, NJ / ACCESSWIRE / July 26, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host two Virtual Investor Spotlight events on Thursday, July 27, 2023 at 11:00 AM ET and 1:00 PM ET. (Details below).

JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th

- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27 th at 1:00 PM ET

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event

- Live moderated webcast with members of the GRI Bio , Inc. management team on Tuesday, July 11 th at 2:00 PM ET

GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series

- U.S. p atent i ssuance for l ead p rogram, GRI-0621 , i n development for the treatment of idiopathic pulmonary fibrosis (IPF )

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

- Live webcast fireside chat on Thursday, June 22 nd at 12:0 0 PM ET

GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Company reiterates commitment to providing much-needed treatment options for i nflammatory, f ibrotic and a utoimmune d iseases

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

Rapidly advancing c linical pipeline in potential high-value i nflammatory, f ibrotic and a utoimmune d iseases

GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

- L ive moderated webcast w i th members of the GRI Bio management team on Wednesday, May 3 rd at 2:00 PM ET

GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm

GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer

LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla V. Simpson, M.Sc. to the Company's Board of Directors. Mr. Szekeres will serve as Chairman of the Board. As previously announced, GRI Bio will commence trading on The Nasdaq Capital Market under the ticker symbol “GRI”, effective today, April 24, 2023, as a result of its recently completed its merger with Vallon Pharmaceuticals, Inc.

GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry

Alpine Global Premier Properties Fund

JPMorgan BetaBuilders MSCI US REIT ETF

Direxion Daily Real Estate Bull 3x Shares

Direxion Daily Real Estate Bear 3x Shares

WisdomTree Global ex-US Real Estate Fund

First Trust FTSE EPRA/NAREIT Developed Markets Real Estate

Fidelity MSCI Real Estate ETF

First Trust S&P REIT Index Fund

Xtrackers International Real Estate ETF

iShares Cohen & Steers REIT ETF

iShares International Developed Real Estate ETF

CBRE Global Real Estate Income Fund

iShares U.S. Real Estate ETF

Nuveen Real Asset Income & Growth Fund

Nuveen Real Estate Income Fund

Invesco KBW Premium Yield Equity REIT ETF

UBS London ETRACS Monthly Pay 2xLeveraged MSCI US REIT Index ETN 2015-5.5.45 Sr Lkd to MSCI US REIT Index Series A Var Rt

Neuberger Berman Real Estate Securities Income Fund Inc

US Diversified Real Estate ETF

Invesco Active US Real Estate

iShares Global REIT ETF

ProShares Short Real Estate

Cohen And Steers Total Return Realty Fund

RMR Real Estate Income Fund

Where To Find Value In REITs

ALPS Emerging Sector Dividend Dogs ETF

ALPS International Sector Dividend Dogs ETF

ALPS Sector Dividend Dogs ETF

The ALPS REIT Dividend Dogs ETF (NYSEArca: RDOG) is one of the newest real estate investment trust (REIT) ETFs on the block, having recently debuted as the replacement for the ALPS ETF Trust Cohen & Steers Global Realty Majors ETF (NYSEArca: GRI).

A Rookie Real Estate ETF Worth Considering

iShares International Developed Property ETF

As global rates are likely to remain low and some developed economies have come up with upbeat first-quarter growth, investors can play the global real estate ETFs for income and capital gains.

4 Global REIT ETFs for Solid Income & Capital Gains

News for GRI Bio Inc Stock (GRI)